Literature DB >> 12573615

In vivo transduction of photoreceptors or ciliary body by intravitreal injection of pseudotyped adenoviral vectors.

Dan J Von Seggern1, Edith Aguilar, Karen Kinder, Shonna Kaye Fleck, J C Gonzalez Armas, Susan C Stevenson, Peter Ghazal, Glen R Nemerow, Martin Friedlander.   

Abstract

Strategies for retargeting adenoviral (Ad) vectors have been developed, but their in vivo efficacy remains to be demonstrated. Gene delivery to specific ocular cell types represents an approach to treating many diseases that cause irreversible blindness. One of these cell types, the photoreceptor (PR), is not infected by standard Ad5-based vectors. We evaluated gene delivery after intraocular injection of Ads pseudotyped with three different fiber proteins and found three distinct patterns of infection. An intravitreally injected Ad5 vector readily infected the iris, corneal endothelium, and ciliary body, while few cells in the retina expressed transgene product. In contrast, an Ad3-pseudotyped virus selectively transduced ciliary body, of interest for treating diseases such as glaucoma. A vector pseudotyped with the fiber protein of Ad37 transduced PRs as well as ciliary body. This finding has potential application to the treatment of retinal degenerative or neovascular diseases. These studies demonstrate cell type-selective gene delivery in vivo with retargeted Ads, provide information about the cellular tropisms of several Ad serotypes, and should lead to improved strategies for preserving vision.

Entities:  

Mesh:

Year:  2003        PMID: 12573615     DOI: 10.1016/s1525-0016(02)00030-8

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  9 in total

Review 1.  Current status of gene delivery and gene therapy in lacrimal gland using viral vectors.

Authors:  Shivaram Selvam; Padmaja B Thomas; Sarah F Hamm-Alvarez; Joel E Schechter; Douglas Stevenson; Austin K Mircheff; Melvin D Trousdale
Journal:  Adv Drug Deliv Rev       Date:  2006-09-15       Impact factor: 15.470

Review 2.  Let There Be Light: Gene and Cell Therapy for Blindness.

Authors:  Deniz Dalkara; Olivier Goureau; Katia Marazova; José-Alain Sahel
Journal:  Hum Gene Ther       Date:  2016-02       Impact factor: 5.695

Review 3.  Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients.

Authors:  Pasqualina Colella; Alberto Auricchio
Journal:  Hum Gene Ther       Date:  2012-08       Impact factor: 5.695

Review 4.  Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies.

Authors:  Anneke I den Hollander; Aaron Black; Jean Bennett; Frans P M Cremers
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

Review 5.  Barriers for retinal gene therapy: separating fact from fiction.

Authors:  Rajendra Kumar-Singh
Journal:  Vision Res       Date:  2008-06-18       Impact factor: 1.886

6.  Adenovirus vectors targeting distinct cell types in the retina.

Authors:  J Harry Sweigard; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-05       Impact factor: 4.799

7.  Lens fiber cell differentiation occurs independently of fibroblast growth factor receptor signaling in the absence of Pten.

Authors:  Stephanie L Padula; Elaine P Sidler; Brad D Wagner; Courtney J Manz; Frank J Lovicu; Michael L Robinson
Journal:  Dev Biol       Date:  2020-08-25       Impact factor: 3.582

8.  Retinal transduction profiles by high-capacity viral vectors.

Authors:  A Puppo; G Cesi; E Marrocco; P Piccolo; S Jacca; D M Shayakhmetov; R J Parks; B L Davidson; S Colloca; N Brunetti-Pierri; P Ng; G Donofrio; A Auricchio
Journal:  Gene Ther       Date:  2014-07-03       Impact factor: 5.250

Review 9.  Vector platforms for gene therapy of inherited retinopathies.

Authors:  Ivana Trapani; Agostina Puppo; Alberto Auricchio
Journal:  Prog Retin Eye Res       Date:  2014-08-12       Impact factor: 21.198

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.